Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

New Company Accepted at the eHealth Ventures Incubator: TrainPain - ?Game Based Neuro-Rehabilitation of Chronic Pain

eHealth Ventures
Posted on: 27 Nov 18
New Company Accepted at the eHealth Ventures Incubator: TrainPain - ​Game Based Neuro-Rehabilitation of Chronic Pain

PR Newswire

TEL AVIV and MODI'IN ILLIT, Israel, November 27, 2018

TEL AVIV and MODI'IN ILLIT, Israel, November 27, 2018 /PRNewswire/ --

eHealth Ventures (, the leading Digital Health technological incubator in Israel, has announced the acceptance of its 7th portfolio company - TrainPain, managed by Dr. Elan Schneider DPT, ​an internationally recognized expert in chronic pain rehabilitation.

TrainPain is developing a novel digital treatment for chronic pain which is one of the greatest health challenges facing humanity. ​ In the U.S. alone, chronic pain affects more than 120 million adults, with an annual cost of over $635 billion. Development of non-pharmacological treatments for chronic pain is high on the global health agenda, and a key component of the NIH strategy for addressing the opioid epidemic. The company received an investment of $1M from eHealth Ventures and Merchavia Holdings and Investments Ltd. (TASE: MRHL), additional financial terms were not disclosed.

TrainPain is dedicated to using technological innovation to translate recent pain neuroscience discoveries into practical and inexpensive solutions for patients. The company's unique technology targets sensory-perceptual processes to reduce pain related hypersensitivity in the nervous system. The platform integrates wearable hardware with personalized sensory training games which enable patients to rehabilitate dysfunctional sensory processing. The rehabilitation platform will be available in both virtual reality and smartphone-based formats for maximum accessibility in the clinic and the patient's home.

The company has several clinical research collaborations ongoing in the U.S. and Europe. Talor Sax, CEO of eHealth Ventures: "We are happy to have received approval for TrainPain. The company is developing a highly disruptive technology that is aimed at one of the biggest​ ​needs​ in healthcare - ​non-pharmacological treatment of chronic pain.​ We have considerable interest from our partners at Maccabi and in the US and we are positive that we can add considerable value to the highly experienced team over the incubator period and beyond."

For additional information, please visit:


Adv. Ophir Shahaf, VP BD, eHealth Ventures -
Dr. Elan Schneider DPT, CEO, Train Pain - ​

SOURCE eHealth Ventures

PR Newswire

Last updated on: 27/11/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.